To address this question, we designed a prospective, polycentric study to evaluate the plasma levels of total ghrelin, ghrelin, and DAG before ASM administration (T0), 2 months (T1), and 12 months (T2) after the onset of ASM treatment in children with epilepsy, defined according to their specific demographic and clinical features. Here, GHRL is linked to epilepsy.